This 980-page report, an
essential tool for making the most successful strategic decisions,
is based on in-depth interviews with 55 HTS directors at pharmaceutical
companies, academic centers, and government institutes worldwide
as well as 32 industry thought leaders.
This report includes
trends in cell-based and biochemical assays; impact of academic
screening centers; trends in target validation, secondary
screening, lead optimization, and early in vitro
ADME/Tox; the increasing use of high content screening (HCS),
compounds and targets, assay and detection trends, label-free
technologies, miniaturization, data handling, budgets and
spending, organization, successes of HTS and future goals.
| |